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Abstract: Eosinophilic colitis (EC) is a common cause of haematochezia in infants and young
children. The exact pathomechanism is not understood, and the diagnosis is challenging. The role
of microRNAs as key class of regulators of mRNA expression and translation in patients with EC
has not been explored. Therefore, the aim of the present study was to explore the miRNA profile in
EC with respect to eosinophilic inflammation. Patients enrolled in the study (n = 10) had persistent
rectal bleeding, and did not respond to elimination dietary treatment. High-throughput microRNA
sequencing was carried out on colonic biopsy specimens of children with EC (EC: n = 4) and controls
(C: n = 4) as a preliminary screening of the miRNA profile. Based on the next-generation sequencing
(NGS) results and literature data, a potentially relevant panel of miRNAs were selected for further
measurements by real-time reverse transcription (RT)-PCR (EC: n = 14, C: n = 10). Validation by
RT-PCR resulted in significantly altered expression of miR-21, -31, -99b, -125a, -146a, -184, -221,
-223, and -559 compared to controls (p ≤ 0.05). Elevation in miR-21, -99b, -146a, -221, and -223
showed statistically significant correlation to the extent of tissue eosinophilia. Based on our results,
we conclude that the dysregulated miRNAs have a potential role in the regulation of apoptosis
by targeting Protein kinase B/Mechanistic target of rapamycin (AKT/mTOR)-related pathways
in inflammation by modulating Nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB)-related signalling and eosinophil cell recruitment and activation, mainly by regulating
the expression of the chemoattractant eotaxin and the adhesion molecule CD44. Our results could
serve as a basis for further extended research exploring the pathomechanism of EC.
Keywords: eosinophilic colitis; microRNA; haematochezia
1. Introduction
Eosinophilic colitis (EC) is a frequent cause of lower gastrointestinal bleeding in the early years of
life. The main clinical manifestations of EC are diarrhoea, and the presence of small amounts of mucus
and fresh blood in the faeces of otherwise healthy infants [1]. The endoscopic features are generally
intact macroscopic structures with swollen erythematous lymphoid follicles (LNH), patchy granularity,
and aphthous lesions. Histologically, EC is characterized with eosinophil infiltrate [2,3]. The disease
affects both breast-fed and soy or cow’s milk-based formula-receiving children. It has been suggested
that the underlying cause could be a non-IgE-mediated hypersensitivity against unidentified dietary
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antigens in the maternal diet [4]. The most recent study addressing this condition postulated that
the recruitment of eosinophils in the colonic mucosa is affected by the expression of eotaxin-2, and
degranulation of the perineural mast cells are frequent in EC; however, the exact pathomechanism of
EC is unknown, and non-invasive diagnostic tests currently are not available [5–9]. Recently there has
been an exponential rise in EC recognition, with an estimated prevalence of 3.3/100,000 [9].
Therapy of EC is based mostly on dietary alterations in the maternal diet or exclusive
administration of amino acid-based formulas. Our study focused on patients unresponsive to dietary
intervention therapy (both maternal diet restrictions and formula feeding). In these types of cases,
persistent bleeding, weight loss, iron deficiency, and anaemia with thrombocytosis can occur; therefore,
endoscopy can be considered. However, due to the overlapping symptoms of EC with Crohn’s disease
(CD) and several other inflammatory conditions or physical damages of the colon, it is difficult to
establish the final diagnosis [10–13]. This unique and clinically more relevant patient group were
previously characterized in the context of endoscopic mucosal histology [10]. Our recent study is
a continuation of efforts to investigate the characteristics of these patients.
Regarding the genetic background of EC patients, there are only very limited data
available—mostly due to the lack of appropriate tissue specimens [14,15]. However, epigenetic factors
gained more importance in recent years, also exerting remarkable effects in diseases with less significant
genetic exposure. In some cases, these epigenetic regulators are more closely related to the phenotype;
therefore, they have been proposed as suitable biomarkers [16–18].
One of the most evolving research areas in epigenetics is that of microRNAs (miRs), the small
(20–22 bp) noncoding sequences capable of repressing mRNA translation and affecting biological
processes at mRNA and protein level [19]. An increasing number of studies report specific expression
alterations of miRs in different gastrointestinal diseases, including eosinophil-associated disorders
such as airway allergies or eosinophilic esophagitis (EOE) [16,17,20,21]. However, to the best of our
knowledge, data regarding the involvement of miRs in the pathomechanism of EC has not yet been
published [20–22].
Therefore, the major aim of our present study was to identify disease-specific miR expression in
a group of patients with persistent haematochezia after maternal exclusion diet (Figure 1). Differences
may contribute to the diagnostic confirmation of EC in cases with poor progression. Moreover,
we aimed to investigate the pool of potential target genes of the altered miRs to gain insight into the
pathomechanism of EC.
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2. Results
2.1. EC-Specific miR Expression Profile by Next-Generation Sequencing (NGS)
In the EC biopsies, 456 miRs were dysregulated in some extent, of which 79 miRs had a fold change
≥1.5 in EC patients compared to controls (p ≤ 0.05). Seventy-one of these miRs were upregulated, and
eight miRs showed lower expression compared to the controls (Table S1). Based on the results of NGS,
but with molecular biological relevance as a higher priority, nine dysregulated miRs previously
connected to tissue eosinophilia, eosinophil cell-related signalling apoptosis, and inflammation
by previous studies were selected for method validation and further analysis by real-time reverse
transcription (RT)-PCR [20,21,23–32].
2.2. Expression of miRs Selected for Further Analysis by RT-PCR
Similar to the changes found by NGS, the expression of the nine miRs selected for method
validation and further analysis by RT-PCR showed statistically significant differences in the colonic
mucosa of paediatric patients with EC compared to controls (p ≤ 0.05). The expression of miR-21, -31,
-99b, -125a, -146a, -184, -221, and -223 was significantly elevated, and that of miR-559 significantly
decreased in the colonic mucosa of children with EC compared to controls (Figure 2).
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Figure 2. Expression of selected miRs in the colonic mucosa of children with eosinophilic colitis (EC)
and controls (C). MiRs were selected based on the results of next-generation sequencing (NGS), and
their colonic expression was validated by real-time reverse transcription polymerase chain reaction
(RT-PCR). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. C.
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2.3. Correlation of miR Expression with Tissue Eosinophil Counts
From the PCR-validated miR panel, expression of miR-21 (r = 0.51; 95% CI = 0.15–0.77; p = 0.009),
-99b (r = 0.60; 95% CI = 0.25–0.81, p = 0.002), -146a (r = 0.62, 95% CI = 0.29–0.82, p = 0.001), -221 (r = 0.78,
95% CI = 0.78, p = 0.53–0.90, p < 0.0001) and -223 (r = 0.59. 95% CI = 0.22–0.81, p = 0.0041) showed
a significantly positive correlation with the number of eosinophil granulocytes in paediatric patients
with EC. MiR-125a, -31, -184, and 559 showed similar tendency, but the correlations with eosinophil
numbers were statistically not significant (Figure 3).
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Figure 3. Correlation of miR-21, -99b, -146a, -221, and -223 with the extent of tissue eosinophilia
in the colonic mucosa of paediatric patients with eosinophilic colitis. Class I: 0–10 eosinophil/high
power field (eo/HPF), Class. II: 10–20 eo/HPF, Class III: 20–40 eo/HPF, Class IV: >40 eo/HPF, area of
HPF = 0.2 mm2. Solid lines represent a regression line with dotted lines depicting 95% CI.
2.4. Results of Bioinformatics Analysis
MiRTarBase database contained 386 reporter assay validated targets of the NGS miR profile found
in EC. From this list expression of 100 entities were reported in epithelial tissue. Annotation of these
100 entities with gene ontology (GO) terms (biological process domain), and enrichment analysis
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resulted in 24 GO term categories. The most abundant terms were connected with immune response,
regulation of apoptosis, transcription regulation, and cell proliferation (Table S2).
3. Discussion
EC in infancy is in most cases a benign self-limiting disease associated with abdominal pain, intestinal
dismotility, and mucosal eosinophilia occurring predominantly in the first six months of life [2]. However,
several cases with overall poor progression and persistent rectal bleeding were reported (including in
our study population). It is of high importance to investigate the pathomechanism and explore the
diagnostic potential regarding these particularly sensitive patients. The exact pathomechanism of EC is
not understood, and its causative therapy is not available in many cases [10,11,33].
Recently, the role of epigenetic factors came into focus as key determinants in the pathogenesis of
different gastrointestinal diseases, including IBD and EOE, frequent forms of eosinophil-associated
gastrointestinal disorders (EGID), and bronchial asthma. The expression of several miRs showed
a strong correlation with the extent of eosinophil infiltration in the biopsy samples of patients with EOE,
and were also dysregulated in their serum [21]. In the current study, we screened the miRNA profile
on low patient count in EC with NGS, and based on these preliminary results, we selected a panel of
miRNAs strongly connected with eosinophilic inflammation for further analysis. We analysed the
selected miRNA with RT-PCR methods on a higher patient number. The panel consisted of nine miRs:
miR-21, -31, -99b, -125a, -146a, -184, -221, -223, and -559. Dysregulation of six of these miRs—miR-21,
-99b, -125a, -146a, -221, and -223—were previously reported in EOE [20,21]. We selected three additional
miRs with strong connection to eosinophil cell recruitment and activation, as described earlier in other
conditions. [28,29,32]. The selected miRs also have several potential effects in the modulation of
inflammatory pathways not directly affecting eosinophil cells. In the following paragraphs, we will
discuss the potential target points, starting with the general pathways of apoptosis followed by the
closely relevant molecular events of eosinophilic inflammation.
From the selected miR panel, miR-21, -99b, and -221 are closely related to apoptosis by the
potential regulation of the PI3K/Akt/mTOR pathway [34–36]. Negative regulation of apoptosis in
lymphoid cells and eosinophils could contribute to their accumulation and prolonged survival in
the colonic tissue [37]. This mechanism could also be an important factor in tissue infiltration and
the subsequent formation of LNH—a frequent endoscopic finding in EC. MiR-559 is an inhibitor
of ERBB2 expression. Eosinophil peroxidase—a secreted effector molecule of activated eosinophil
cells—is a ligand of ERBB2, and the downstream signalisation originating from ERBB2 has significant
proliferative effects; hence, it could contribute to the dwelling caused by prolonged accumulation and
activation of eosinophils on inflammatory sites [28].
On the other hand, positive regulation of apoptosis—on which the dysregulated miRs could
also have a potential effect according to our present analysis—could slow down the turnover and
proliferation of epithelial cells in the colonic tissue, leading to the impairment of intestinal barrier
function and the facilitation of inflammatory processes [38–40]. This phenomenon as a histologic
finding has been reported in connection with EC. Apoptotic cell-specific histochemical TUNEL assay
on biopsies labelled with epithelial cell-specific antibodies identified an increased number of apoptotic
epithelial cells in the lamina propria of rectosigmoid biopsy specimens originating from infants with
haematochezia previously diagnosed with allergic/eosinophilic colitis [40].
Similar to the observations in EOE, in the present study we demonstrated significantly elevated
expression of miR-21, -146a, and -223 in the colonic mucosa of paediatric patients with EC compared to
controls, and it was strongly correlated with the extent of tissue eosinophilia. Furthermore, we found
a positive correlation between the expression changes of miR-99b and -221 and the number of tissue
eosinophils in the colonic mucosa of EC patients [41,42] (Figure 3). The correlations suggest that these
miRs could be actively connected to the pathomechanism of EC. A composite graph of the possible
interacting points of these miRs with respect to inflammation and tissue eosinophilia is presented in
Figure 4.
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(IκB), phosphatase and tensin homolog (PTEN), phosphatidylinositol (3,4,5)-trisphosphate (PIP3),
phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol-3-kinase (PI3K), phosphoinositide
dependent protein kinase (PDK), programmed cell death protein 4 (PDCD4), protein kinase B (Akt),
receptor activator of nuclear factor kappa-B ligand (RANKL), TNF receptor associated factor-6 (TRAF6),
Toll-like receptor-1-2, 4-6 (TLR 1-2, 4-6), tumor necrosis factor alpha (TNFα), tumor necrosis factor,
α-induced protein 3 (A20).
Certain dysregulated miRs in the colonic mucosa of children with EC (e.g., miR-125a, -146a, and
-223 as identifie in o r present experiments) are also related to eosinophil cell line differentiation,
activation, and recruitment [37]. Lu et al. fou d a connecti n between miR-223 eficiency and
in reased eosinophil progenitor cell prolifer ti n in an x vivo bone marrow-derive eosinophil
culture system [43]. It is inferr d from bone marrow culture experiments tha miR-125a and -146a
are also parts of he regulation network of eosinophil cell maturation [41]. To further inv stigate the
relationship between miRs and eosinophil function i EC, additional studies would be needed on
eosinophil granulocytes freshly isolated from the colonic tissues of EC patients.
MiR-21 has been reported to be the most frequently upregulated miR in eosinophil-related
diseases [21,23]. It is a complex regulator of eosinophil cell fate, activation and survival. MiR-21
overexpression is able to increase eosinophil progenitor cell growth, it has a pro-survival effect on
eosinophils via granulocyte-macrophage colony-stimulating factor (GM-CSF), and acts towards Th2
polarization of the adaptive immune processes [23,25–27].
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The correlation of miR-221 expression with airway tissue eosinophilia has been reported in
a murine model of bronchial asthma. In this model, the level of miR-221 was also correlated
with IL-4 secretion, presumably via phosphatase and tensin homolog (PTEN) and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) protein related pathways that are potent
inductors of tissue eosinophil infiltration [42]. Increased prevalence of EC has been reported amongst
patients with PTEN hamartoma tumour syndromes [44]. MiR-21 and -221 are two miRs which
showed significant elevation according to our measurements, and have been connected to the
regulation of PTEN gene expression [36,45]. PTEN protein is a mon-redundant master regulator
of the PI3K signalling pathway. Humans are highly sensitive of PTEN dosage, and alterations in the
PI3K/Akt/mTOR pathway has been connected to eosinophil cell-related conditions [46–48]. MiR-99b
is a member of the miR-99 family, and is also a potent regulator of the PI3K/Akt/mTOR pathway.
Besides the effects on eosinophil cell survival, this pathway is active in the tissues of inflammation
sites, acting as a mediator of wound healing [35].
MiR-184 targets the NFAT1 transcript directly. Deficiency in the NFAT1 protein product could
lead to elevated IL-5, IL-2, and IL-13 production. These cytokines promote eosinophil cell survival and
recruit via upregulation of eotaxin levels [28].
MiR-31 levels are positively correlated with the expression of CD44 adhesion molecule, a promoter
of tissue eosinophilia. Expression of CD44 in epithelial cells could promote eosinophil migration and
activation [31]. It has been demonstrated that changes in CD44 adhesion molecule levels in epithelial
cells is a major component of tissue alterations in EOE, and promotes eosinophil and leukocyte
migration and activation on the site of inflammation [32].
A limitation of our present study is that biopsies from age-matched healthy subjects could not
be obtained. However, we enrolled the youngest possible patients to the control group in order
to minimize these effects on the results. To completely eliminate the possible effect of age-related
differences, only samples originating from autopsy procedures of infants involved in accidents or who
suffered sudden infant death would be completely applicable.
In summary, to the best of our knowledge, we conducted the first experiments in order to
define the miR profile specific to EC. Using bioinformatics tools, we assessed the pool of target genes
potentially affected by the miRs dysregulated in the colon of children with EC having persistent rectal
bleeding, unresponsive to dietary therapies. Our results defined several possible target point for miRs
on the molecular biological events of eosinophilic inflammation, and therefore could serve as a base
for further investigations of the pathomechanism of EC.
4. Materials and Methods
4.1. Patients
Samples from all patients enrolled in the study were obtained at the 1st Department of Pediatrics,
Semmelweis University, Budapest, Hungary. Colon pinch biopsies were taken from 10 children with EC
and 14 controls. Clinical characteristics and laboratory parameters of the patients are shown in Table 1.
Patients enrolled in the study had persistent rectal bleeding, and they were unresponsive to dietary
intervention therapies. Patients underwent colonoscopy in order to exclude IBD and other organic
causes of long-lasting haematochezia. The overall symptoms, long term follow-up, and endoscopic
features of the patients did not justify the consideration of monogenic origin. Subsequent diagnosis of
CD (without monogenic cause) was obtained in one patient, who was therefore excluded from the study.
Diagnosis of EC was based on clinical history, physical examination (no perianal fissure), laboratory
findings (infections excluded), endoscopic findings (focal erythema, LNH, and aphta), and pathological
evaluation of tissue specimens (average eosinophil count/five high power field (eo/HPF) > 20, HPF
area = 0.2 mm2) with long-term follow-up of the patients. Microscopic evaluation was open-label
conducted by a skilled pathologist as a part of diagnostic processes. Control children underwent
colonoscopy to assess the cause of failure to thrive or suspicion of polyp or Meckel-diverticulum.
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All specimens in the control group showed normal macroscopic and histologic features. Biopsies were
immediately snap-frozen and stored at −80 ◦C until further experiments. Written informed consent
was obtained from the parents prior to the procedure, and the study was approved by the Semmelweis
University Regional and Institutional Committee for Research Ethics (TUKEB No.: 10408/2012, Date:
30 March 2012).
Table 1. Clinical characteristics and laboratory parameters of patients enrolled in the study (A) in the
next-generation sequencing groups; and (B) in the real-time reverse transcription polymerase chain
reaction validation groups. BMI: body mass index, CRP: C-reactive protein; Data are presented as
mean ± SD * p ≤ 0.05 vs. Control, *** p ≤ 0.0001 vs. Control.
A Control Eosinophilic Colitis
n 4 4
Male/Female 2/2 3/1
Age (months) 136.5 ± 35.78 8.88 ± 5.14 *
BMI (kg/m2) - 18.66 ± 3.79
Iron (µmol/L) 10.75 ± 2.5 13.25 ± 3.57
Albumin (g/L) 51.75 ± 8.81 -
Haemoglobin (g/L) 134.3 ± 7.76 121.8 ± 3.64
Haematocrit (%) 0.39 ± 0.02 0.34 ± 0.013
Platelet count (Giga/L) 325.8 ± 21.10 440.5 ± 57.81
CRP (mg/L) 1.25 ± 1.4 0
B Control Eosinophilic Colitis
n 14 10
Male/Female 6/8 8/2
Age (months) 29.82 ± 17.08 5.7 ± 4.76 ***
BMI (kg/m2) 16.15 ± 1.6 16.21 ± 1.74
Length-weight percentile (%) -
42.25 ± 34.92
1/10 overweight
1/10 underweight
Iron (µmol/L) 15.70 ± 4.9 9.89 ± 5.62 *
Albumin (g/L) 45.8 ± 2.01 44 ± 4.24
Haemoglobin (g/L) 122.1 ± 12.26 112.6 ± 8.32 *
Haematocrit (%) 35.18 ± 2.8 32 ± 1.94
Platelet count (Giga/L) 364.6 ± 87.09 394.5 ± 104.1
CRP (mg/L) 0.79 ± 1.4 3.44 ± 8.49
4.2. RNA Isolation
Total RNA isolation from the colonic biopsies was conducted with TRIzol reagent (Ambion,
Austin, TX, USA) for the next-generation sequencing (NGS) and Quick-RNA MiniPrep isolation kit
(Zymo Research, Irvine, CA, USA) for the real-time reverse transcription polymerase chain reaction
(RT-PCR) measurements, according to the manufacturer’s protocol.
4.3. cDNA Library Preparation and NGS
A cDNA library for small RNA-Seq was generated from 1 µg total RNA samples derived from the
colonic mucosa of paediatric EC patients (EC: n = 4) and controls (C: n = 4) using TruSeq Small RNA
Sample Preparation Kit (Illumina, San Diego, CA, USA) according to the manufacturer’s protocol.
Fragment size distribution and molarity of libraries were checked on Agilent BioAnalyzer DNA1000
chip (Agilent Technologies, Santa Clara, CA, USA). Concentration of small RNA libraries were set
to 10 nM, and cluster generation was done using TruSeq SR Cluster kit v3-cBot-HS kit on cBot
instrument, then a single read 50 bp sequencing run was performed on Illumina HiScan SQ instrument
(Illumina, San Diego, CA, USA) carried out by UD-GenoMed Medical Genomic Technologies Ltd.
(Debrecen, Hungary).
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4.4. RT-PCR
RT-PCRs were performed on colonic biopsy samples of EC patients (n = 14) and controls
(n = 10). Total RNA was reverse-transcribed using TaqMan MicroRNA Reverse Transcription Kit
(Life Technologies, Carlsbad, CA, USA). MiRs were selected for validation according to the NGS
results, and their expression was determined by RT-PCR using TaqMan Universal PCR Master Mix No
AmpErase UNG (Life Technologies). Measurements were carried out on a LightCycler 480 instrument
(Roche, Basel, Switzerland). Relative expression level was calculated by the ∆∆Cq formula, using U6 as
an internal standard. TaqMan miR assays (miR-21: ID: 000397, miR-31: ID: 002279, miR-99b: ID: 000436,
miR-125a: ID: 002198, miR-146a: ID: 000468, miR-184: ID: 000485, miR-221: ID: 000524, miR-223: ID:
002295, miR-559: ID: 001527, U6: ID: 001973) were used according to the manufacturer’s instructions.
4.5. Bioinformatics Analysis of the Whole NGS miR Profile
Experimentally validated (reporter assay) target genes were selected from the MiRTarBase
database (Available online: http://mirtarbase.mbc.nctu.edu.tw) [49]. Target genes were filtered
for site of expression reported according to the tissue expression database of UniProt (Available online:
http://www.uniprot.org) [50]. The Database for Annotation, Visualization and Integrated Discovery
(DAVID) bioinformatics tool was used to annotate the resulting list in the Biological process domain
of the Gene Ontology (GO) database [51–54]. Enrichment analysis was carried out on the results with
an established 0.01 threshold of the modified Fisher Exact p-value (EASE) scores of the enriched categories
adjusted with the Benjamini–Hochberg correction method, and 10 entities threshold for group count.
4.6. Determination of Eosinophil Counts in the Colonic Tissue of EC Patients
Colonic tissue eosinophil counts were assessed in the microscopic slides by a pathologist with
an assumption of representativeness. Evaluation of the specimens was open-label and conducted
as a part of the normal diagnostic procedure. Paraffin-embedded tissue samples and fresh-frozen
specimens were taken within close vicinity of each other. Eosinophil cells were detected by standard
Hematoxylin and Eosin (H&E) staining (ST5020 Multistainer, Leica Microsystems GmbH, Wetzlar,
Germany). Eosinophils in the lamina propria were counted in five random high-power fields (HPF:
area of tissue covered by a ×40 light microscope objective: 0.2 mm2) selected from an eosinophil-dense
part of the slides, on optical microscopy (BX51TF, Olympus, Tokyo, Japan). More than 20 eo/HPF was
the cut-off number for EC (reference of histological evaluation presented in Figure 5). Based on the
average number of eosinophil granulocytes in five HPFs (HPF area = 0.2 mm2), patients were divided
into four categories (Class I: 0–10 eo/HPF, Class II: 10–20 eo/HPF, Class III: 20–40 eo/HPF, Class IV:
>40 eo/HPF).
Correlation between tissue eosinophil counts and miR expressions was calculated using
a Spearman method assuming Gaussian distribution of the data.
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4.7. Statistical Analysis 
Statistical analysis was performed using the GraphPad statistical software package (GraphPad 
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